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A B S T R A C T   
Avascular necrosis of the femoral head is a well-known complication of treatment with high dosage glucocor-
ticoids and has been described in a few patients with Cushing’s syndrome. In this case report, we describe the, to 
our knowledge, first case of a patient with endogenous Cushing’s syndrome with a bone infarction located in the 
distal femur. In patients with Cushing’s syndrome and bone pain, the diagnosis of bone infarction should be 
considered as it can occur as a rare complication of hypercortisolism.   
1. Introduction 
The use of glucocorticoids is associated with the development of 
bone infarction, also known as osteonecrosis or avascular necrosis 
(AVN). Avascular necrosis of the femoral head, which is one of the most 
commonly affected localizations, is a well-known complication of 
treatment with high dosage glucocorticoids and has been described in a 
few patients with endogenous Cushing’s syndrome (Belmahi et al., 
2018; Bukhman et al., 1987; Camporro et al., 2016; Cerletty et al., 1973; 
Güven et al., 2009; Ko et al., 2004; Kobayashi and Terayama, 1991; 
Koch et al., 1999; Modroño et al., 2014; Pazderska et al., 2016; Phillips 
et al., 1986; Premkumar et al., 2013; Sharon et al., 1977; Takada et al., 
2004; Wicks et al., 1987). Here, we present a case of a 22-year old male 
patient with severe hypercortisolism due to Cushing’s disease, who 
developed a spontaneous bone infarction of the distal femur. 
2. Case description 
A 22-year old male patient with no previous medical history was 
referred to our tertiary center with suspicion of Cushing’s syndrome. 
During the last two years, he suffered from complaints of fatigue, gain of 
weight (10 kg) and psychological problems. Physical examination 
showed a cushingoid appearance with full moon face, supraclavicular 
fat pads, abdominal obesity, proximal muscle wasting, reddish-purple 
striae at the abdomen and upper arms, cutaneous fungal infection and 
hematomas. Biochemical analysis confirmed ACTH dependent severe 
hypercortisolism: cortisol concentration after 1 mg dexamethasone 
suppression test (DST) was 0.61 μmol/l (normal value (n) <0.05 μmol/ 
l), 24-h urine free cortisol level was 2260 nmol (n < 150 nmol), late 
night salivary cortisol concentration was 39.0 nmol/l (n < 3.0 nmol/l) 
and adrenocorticotropic hormone (ACTH) concentration was 28.8 
pmol/l (n 1.6–13.9 pmol/l) (Nieman et al., 2008). Pituitary MRI showed 
a lesion of 8 × 5 mm in the anterior pituitary gland and the patient was 
referred to the neurosurgeon for resection of the adenoma. Endoscopic 
endonasal transsphenoidal surgery was performed followed by remis-
sion of Cushing’s syndrome. Pathological examination of the resected 
tissue showed an ACTH-producing adenoma. 
For 5 months prior to the diagnosis of Cushing’s disease, the patient 
suffered from pain in his left upper leg, for which he was referred to the 
orthopedic surgeon. Physical examination showed normal knee function 
without swelling or pain. There was no axial pressure pain in the upper 
leg. 
Conventional X-ray of the distal femur showed a probable sheath-like 
intramedullary lucency, which was only recognized in retrospect after 
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magnetic resonance imaging (MRI) (Fig. 1). MRI showed a 10 cm cra-
niocaudal area of serpiginous unsharp PD- and T2-hyperintense and T1- 
intermediate intense lines surrounding normal fatty bone marrow in the 
distal femoral metadiaphysis (Fig. 2). There were no peripheral low- 
signal intensity lines, confirming lack of sclerosis on conventional X- 
rays and consistent with early bone marrow infarction. 
The bone infarction was treated conservatively. Six months later, a 
follow-up MRI showed a much smaller abnormal intramedullary area of 
sharp T2-hyperintense and T1-hypointense lines, consistent with heal-
ing bone infarction. 
3. Discussion 
To our knowledge this is the first described case of a patient with 
endogenous Cushing’s syndrome and bone infarction located in the 
distal femur. However, avascular necrosis of the femoral head has been 
described in some patients with endogenous Cushing’s syndrome (Bel-
mahi et al., 2018; Bukhman et al., 1987; Camporro et al., 2016; Cerletty 
et al., 1973; Güven et al., 2009; Ko et al., 2004; Kobayashi and Ter-
ayama, 1991; Koch et al., 1999; Modroño et al., 2014; Pazderska et al., 
2016; Phillips et al., 1986; Premkumar et al., 2013; Sharon et al., 1977; 
Takada et al., 2004; Wicks et al., 1987). Cushing’s syndrome is a rare 
endocrine disorder that is characterized by signs and symptoms of 
hypercortisolism. It is most commonly caused by an ACTH producing 
adenoma of the anterior pituitary gland, which is known as Cushing’s 
disease (Lindholm et al., 2001). Less common etiologies of Cushing’s 
syndrome are cortisol producing adrenal tumors, adrenal hyperplasia 
and ACTH-producing ectopic tumors. 
Bone infarctions are commonly reported events during treatment 
with high dosage glucocorticoids with a prevalence between 3% and 
38%, depending on the underlying disease and the used dosage of glu-
cocorticoids (Assouline-Dayan et al., 2002). For example, high in-
cidences of bone infarctions are found in pediatric patients treated for 
acute lymphoblastic leukemia (ALL) and in pediatric patients who have 
undergone allogenic bone marrow transplantation (Kaste et al., 2011). 
Both of these groups receive high dosages of glucocorticoids. In addi-
tion, a cohort study in patients with different kind of chronic inflam-
matory diseases showed an association between glucocorticoid exposure 
and avascular necrosis, especially in young adults (Horton et al., 2017). 
Other risk factors include: alcohol abuse, hematological diseases such as 
sickle cell anemia or thalassemia, hypercholesterolemia, chronic renal 
failure, autoimmune diseases, pregnancy and hyperparathyroidism 
(Chan and Mok, 2012; Moskal et al., 1997; Poignard et al., 2012; Wang 
et al., 2003). The knee is the second most common affected localization 
of bone infarctions, although much less common than the hip (Chan and 
Mok, 2012; Mont et al., 2000). Other localizations of bone infarctions 
are the shoulder and ankle. The specific prevalence of bone infarctions 
of the distal femur is not known. 
The pathogenesis of glucocorticoid induced bone infarctions is not 
fully understood. Hypotheses include fat cell hypertrophy, fat emboli-
zation, intravascular coagulation and osteocyte apoptosis (Chan and 
Mok, 2012). Fat cell hypertrophy might increase intramedullary pres-
sure and reduce venous return, which are hypothesized to lead to bone 
infarctions as well (Motomura et al., 2005). One animal study has shown 
that treatment with the low-molecular-weight heparin (LMWH) enox-
aparin (Clexane) has the potential to prevent steroid-induced bone in-
farctions (Beckmann et al., 2014). In the mentioned study, the bone 
infarctions were induced by systemic treatment with methylpredniso-
lone. This might indicate that intravascular coagulation plays an 
important role in the pathogenesis of bone infarctions. Furthermore, 
because of down-regulation of vascular endothelial growth factor, glu-
cocorticoids can induce hypoperfusion of the bone, which might result 
in bone infarction (Wang et al., 2010). Lastly, it is known that hyper-
cortisolism can lead to endothelial dysfunction (Wagenmakers et al., 
2016). Glucocorticoids increase vascular smooth muscle contractility 
and decrease endothelial-dependent vasodilatation (Walker, 2007). One 
could hypothesize that this altered vascular tone might lead to decreased 
blood flow in tissues and thus may contribute to the pathogenesis of 
glucocorticoid induced bone infarctions. 
The golden standard for diagnosing bone infarctions is MRI, while 
conventional X-ray is less sensitive (Kaste et al., 2011). Bone infarctions 
can be managed conservatively or surgically. Indication for one or the 
other depends on stage of disease, size of the lesion, age and comor-
bidities of the patient (Chan and Mok, 2012). If pain relief is required, 
core decompression can be performed. During this procedure intra-
medullary pressure is reduced by making a drill hole, which improves 
blood flow (Chan and Mok, 2012). To strengthen the bone near the joint, 
bone impaction grafting can be performed (Rijnen et al., 2006). If the 
joint has been destroyed by the bone infarction, joint replacement is 
necessary (Chan and Mok, 2012). Furthermore, bisphosphonates may 
reduce pain and improve functionality (Luo et al., 2014). 
4. Conclusion 
In conclusion, the patient presented is to our knowledge the first 
described case of bone infarction of the distal femur in a patient with 
severe endogenous Cushing’s syndrome. In patients with Cushing’s 
syndrome and bone pain, the diagnosis of bone infarction should be 
considered as it can occur as a rare complication of hypercortisolism. 
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